FibroGen (FGEN)
(Delayed Data from NSDQ)
$0.39 USD
0.00 (1.23%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $0.39 0.00 (-1.22%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.39 USD
0.00 (1.23%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $0.39 0.00 (-1.22%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Zacks News
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 38.46% and 53.46%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 33.33% and 1.14%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 2.99% and 2.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
by Zacks Equity Research
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
by Zacks Equity Research
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
by Zacks Equity Research
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
by Zacks Equity Research
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
by Zacks Equity Research
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals
by Zacks Equity Research
Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
by Zacks Equity Research
Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
by Zacks Equity Research
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
by Zacks Equity Research
RallyBio (RLYB) gains 83% after announcing a collaboration deal with J&J to develop novel therapies to reduce the risk of FNAIT in pregnant women, along with funding of $6.6 million from the latter.
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
by Zacks Equity Research
Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Entera Bio Ltd. (ENTX) and FibroGen (FGEN) have performed compared to their sector so far this year.
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
by Zacks Equity Research
Eyenovia (EYEN) plunges 18% after sharing plans to consider strategic alternatives involving the sale of the company or assets, amid a severe cash crunch and poor performance of marketed drugs.
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
by Zacks Equity Research
Ocugen (OCGN) stock gains as the DSMB for the phase I/II study of OCU410 approves the initiation of dosing with the medium dose of OCU410 in the dose-escalation phase of the GA study.
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
by Zacks Equity Research
Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024.
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
by Zacks Equity Research
eFFECTOR Therapeutics (EFTR) plunges on disappointing top-line results from the primary analysis of its mid-stage NSCLC study of tomivosertib, following the abandonment of the developmental program.
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
by Zacks Equity Research
Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
by Zacks Equity Research
Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
by Zacks Equity Research
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
by Zacks Equity Research
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
by Zacks Equity Research
Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
by Zacks Equity Research
Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
by Zacks Equity Research
Hoth Therapeutics (HOTH) rises on encouraging pre-clinical data demonstrating cognitive benefits of its novel therapeutic candidate, HT-ALZ, in the treatment of Alzheimer's disease.